@entity29601 given as a continuous infusion is an active agent for relapsed adult XXXX .

@entity1 @entity137 @entity981 @entity882 @entity19 @entity29601 @entity9638 @entity3052 @entity1778 @entity236 @entity1860 @entity3894
@entity29601 given as a bolus has not been effective in @entity1 with relapsed or @entity1778 . Because of in vitro data suggesting enhancement of @entity29601 -induced @entity137 for @entity1 and @entity19 @entity1778 cells with increased duration of drug exposure and the relatively short terminal plasma half-life of @entity29601 , 49 @entity1 (34 @entity3052 [ @entity3052 ], six @entity1860 in @entity9638 [CML-B], five @entity981 [ @entity981 ], four 2 degrees @entity3052 ) with @entity1778 were given @entity29601 as a continuous infusion for seven days. The maximum tolerated dose was 28 mg/m2/d for seven days. The dose-limiting @entity137 was the duration of @entity236 (median, 49 days to greater than 500 PMNs in responders; range, 28 to 101 days). Nonhematologic @entity137 was minimal. Responses occurred only in @entity1 with relapsed @entity3052 , of whom 26 were treated at effective doses. There were six complete responses (CR) (23%) and two partial responses (PR) (8%), although five of eight responders never achieved platelet counts greater than 100,000/microL. @entity882 in these @entity1 was felt to be a manifestation of @entity29601 effect, not persistence of @entity1778 . The median duration of CR was 195 days (range, 88 to 860+). One @entity1 had @entity1778 at the start of treatment and has had a durable (28+ month) CR in both sites of disease. @entity29601 produced prolonged @entity3894 in @entity1 with secondary @entity3052 and CML-B (five of ten @entity1 died aplastic), whereas @entity1 with @entity981 all had regrowth of @entity1778 and two failed to become aplastic. The lack of significant nonhematologic @entity137 and the activity in @entity1 with relapsed @entity3052 render @entity29601 of interest as second-line therapy or consolidation therapy in first remission for @entity1 with @entity3052 .
